Ownership and insider activity for Immatics N.V. (IMTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials.
Price
| Price | $8.64 |
| Market Cap | $1.2B |
| Exchange | NASDAQ |
| Country | DE |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.4M | $103.4M | $207.5M | $133.0M | $148.5M | $218.5M | $236.7M | $345.8M |
| Short-term Investments | $13.1M | $16.0M | $24.4M | $12.1M | $213.7M | $207.4M | $367.7M | $123.4M |
| Receivables | $1.8M | $2.7M | $2.9M | $2.4M | $1.1M | $5.7M | $6.7M | $6.9M |
| Inventory | 0 | $1.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $55.3M | $124.0M | $239.0M | $152.2M | $377.2M | $449.4M | $629.6M | $503.8M |
| Property, Plant & Equipment | $4.0M | $8.0M | $14.0M | $20.5M | $26.5M | $57.1M | $63.7M | $54.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $1.0M | $1.0M | $913000 | $1.3M | $1.6M | $1.5M | $1.6M | $1.6M |
| Total Assets | $61.3M | $134.3M | $254.6M | $174.6M | $407.8M | $510.0M | $696.1M | $562.1M |
| Accounts Payable | $4.8M | $4.9M | $2.6M | $3.0M | $13.1M | $7.7M | $10.1M | $339855 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $26.8M | $69.3M | $77.5M | $95.1M | $106.5M | $156.6M | $68.0M | $43.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $70.5M | $175.1M | $167.3M | $150.6M | $204.5M | $292.3M | $121.3M | $78.2M |
| Retained Earnings | -$201.6M | -$233.2M | -$444.5M | -$537.8M | -$510.1M | -$604.8M | -$589.5M | -$785.7M |
| Total Equity | -$10.4M | -$41.9M | $87.4M | $24.1M | $203.4M | $217.6M | $574.8M | $483.9M |
| Total Debt | 0 | $3.2M | $6.2M | $9.9M | $14.6M | $15.4M | $16.2M | $15.6M |
| Net Debt | -$52.5M | -$116.1M | -$225.8M | -$135.3M | -$347.6M | -$410.5M | -$588.2M | -$453.5M |
| Working Capital | $28.5M | $54.7M | $161.5M | $57.1M | $270.7M | $292.8M | $561.6M | $460.8M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 7.54 |
Profitability
| Return on Equity | -47.04% |
| Return on Invested Capital | -52.53% |
| Return on Assets | -42.54% |
| Gross Margin | 100.00% |
| Operating Margin | -543.79% |
| Net Margin | -495.27% |
Related companies: ATAI · CVAC · ELVN · INBX · NKTR · PGEN · RLAY
Explore sector: Healthcare · Biotechnology
More sections of IMTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks